LENSAR Inc

LNSR

Add to Watchlist

5.540USD

-0.290-4.97%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

LENSAR Inc's Score

Industry at a Glance

Industry Ranking

78 / 206

Overall Ranking

194 / 4482

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

LENSAR Inc Highlights

StrengthsRisks

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.17% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.16M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.16M.

Overvalued

The company’s latest PE is 2.27, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.68M shares, decreasing 4.88% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 856.22K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.08.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.500

Target Price

+45.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of LENSAR Inc is 6.35, ranking 152 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 13.43M, representing a year-over-year decrease of 5.16%, while its net profit experienced a year-over-year decrease of 232.87%.

Score

Industry at a Glance

Previous score

6.35

Change

0



Financials

4.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.53

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.04

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of LENSAR Inc is 6.73, ranking 151 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 2.27, which is 6.13% below the recent high of 2.41 and 372.89% above the recent low of -6.19.

Score

Industry at a Glance

Previous score

6.73

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 78/206

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of LENSAR Inc is 9.00, ranking 8 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of LENSAR Inc is 7.33, ranking 49 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 6.09 and the support level at 5.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.09

Change

-1.76

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of LENSAR Inc is 5.00, ranking 110 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 55.41%, representing a quarter-over-quarter increase of 10.86%. The largest institutional shareholder is Brandes Investmen, holding a total of 856.22K shares, representing 7.07% of shares outstanding, with 53.14% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

North Run Capital, LP

1.10M

--

Brandes Investment Partners, L.P.

Star Investors

856.22K

+10.10%

Curtis (Nicholas T)

792.29K

--

BlackRock Institutional Trust Company, N.A.

585.69K

+1.76%

Link (William J)

543.27K

-1.34%

Connaughton (Alan B.)

274.57K

-0.86%

Lindstrom (Richard L)

239.04K

-2.99%

Dimensional Fund Advisors, L.P.

224.93K

--

Geode Capital Management, L.L.C.

217.73K

-0.07%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LENSAR Inc is 4.05, ranking 112 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. LENSAR Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

LENSAR Inc

LNSR

6.77 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.68 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bruker Corp

BRKR

8.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment